To evaluate the clinical efficacy of Qidan Tangshen granules in patients with diabetic nephropathy(DN)with Qi deficiency, blood stasis, and kidney deficiency syndrome.
A total of 86 DN patients with Qi deficiency, blood stasis, and kidney deficiency syndrome who visited the department of endocrinology, Longhua hospital affiliated to Shanghai university of traditional Chinese medicine(TCM) from January 2024 to January 2025 were enrolled and randomly assigned to the control group and the treatment group using block randomization, with 43 patients in each group.On the basis of standard treatment, the treatment group additionally received Qidan Tangshen granules, while the control group received a placebo preparation. Both groups received a treatment duration of 12 weeks. After treatment, urinary albumin-creatinine ratio(UACR), glomerular filtration rate(GFR), serum β2-microglobulin(β2-MG), insulin-like growth factor(IGF)-1, superoxide dismutase(SOD), nitric oxide(NO), glutathione reductase(GR), blood glucose, lipid profile, TCM syndrome scores, and safety parameters were observed and compared between the two groups.
Finally, 42 patients in the treatment group and 43 in the control group completed the trial. After treatment, the levels of UACR, blood glucose, lipid levels, IGF-1, NO, and SOD in the treatment group were all improved compared with those before treatment(P<0.05). Individual TCM symptom scores for sallow complexion, soreness and weakness of waist and knees, and polyphagia were significantly lower than those in the control group(P<0.05). The overall efficacy rate of Western medicine clinical outcomes was higher in the treatment group than that in the control group(83.3% vs. 60.5%, P<0.05), as was the total effective rate of TCM syndrome improvement(81.0% vs. 55.8%, P<0.05). There were no significant differences in safety indicators or incidence of adverse reactions between the two groups(P>0.05).
Qidan Tangshen granules can effectively reduce urinary protein levels in DN patients with Qi deficiency, blood stasis, and kidney deficiency syndrome, improve glucose and lipid metabolism disorders, enhance antioxidant capacity, and significantly alleviate TCM clinical symptoms.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |